New drug combo shows promise for untreatable liver tumors

NCT ID NCT05507632

Ongoing Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is active but no longer recruiting, and results are still being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donafenib plus Sintilimab combined with transarterial chemoembolization (TACE)
What this could lead to: If this works, it could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery, potentially shrinking tumors and extending life.
What could go wrong: This is a small, early-phase study with only 48 participants and no comparison group. The combination may cause significant side effects, and success in this trial does not guarantee broader effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.